Befuraline (DIV-154) is a psychoactive drug and member of the piperazine chemical class which was developed in Germany in the 1970s.[1] Befuraline has stimulant and antidepressant effects and has seen some use in Germany and France, although it has never become widely used.[2] Befuraline's active metabolite benzylpiperazine is likely to contribute to its effects.
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H20N2O2 |
Molar mass | 320.392 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Synthesis
editA one-step coupling between coumarilic acid (benzofuran-2-carboxylic acid) [496-41-3] (1) and benzylpiperazine (BzP) (2) gives an amide, and hence Befuraline (3).
See also
editReferences
edit- ^ a b Boksay IJ, Popendiker K, Weber RO, Söder A (1979). "Synthesis and pharmacological activity of befuraline (N-benzo[b]furan-2-ylcarbonyl-N'-benzylpiperazine), a new antidepressant compound". Arzneimittel-Forschung. 29 (2): 193–204. PMID 582130.
- ^ Gastpar M, Gastpar G, Gilsdorf U (November 1985). "Befuraline, its safety and efficacy in depressed inpatients". Pharmacopsychiatry. 18 (6): 351–5. doi:10.1055/s-2007-1017396. PMID 4089015. S2CID 9322026.
- ^ DE2157424 idem Rolf-Ortwin Weber, Alfons Soder, Istvan Boksay, U.S. patent 4,374,990 (1980 to Hoechst Aktiengesellschaft).